StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
| Metric | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 |
|---|---|---|---|---|
Revenue | $16.14M | $3.44M | $7.57M | $7.22M |
Operating Income | $-6.62M | $-8.13M | $-65.92M | $-54.51M |
Net Income | $204.00K | $-9.74M | $-76.58M | $-60.38M |
EPS (Diluted) | $-1.01 | $-1.03 | $-14.78 | $-12.96 |
Total Assets | $39.11M | $42.18M | $54.13M | $32.93M |
Total Liabilities | $56.59M | $60.75M | $63.99M | $66.98M |
Cash & Equivalents | $15.40M | $29.59M | $46.33M | $22.96M |
Free Cash Flow OCF − CapEx | $-22.72M | Not available | $-60.95M | $-44.89M |
Shares Outstanding | 9.25M | 91.79M | 9.18M | 45.60M |
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $7.37 | $7.15 | -2.99% | 0.0M |
| 05-13 | $6.91 | $7.37 | +6.66% | 0.2M |
| 05-14 | $7.48 | $6.95 | -7.09% | 0.1M |
| 05-15 | $6.85 | $6.27 | -8.47% | 0.1M |
| 05-18 | $6.27 | $6.24 | -0.48% | 0.0M |